>ARRY
I have a position in ARRY, but not anywhere near what might be thought of as core. Lots of shots on goal, yes, but we saw with EXEL over the years that you can have a lot of shots and miss with virtually all of them. So basically it goes in my "basket" category - one of a bunch of biotechs that seem to have a good risk/reward ratio that I'm happy to hold with a modest position in each.
It's very easy to look back a few months and think "why didn't I load up on ARRY in the under-$2 range" but life's too short for me to think that way. Investing is always easy in retrospect, so I try not to beat myself up for what turned out to be sub-optimal decisions.
Peter
Market Data 
Markets 
AI
